Achilles Therapeutics Plc (ACHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
09-2020 | 06-2020 | 03-2020 | 12-2019 | |
Operating Expenses | 8,300 | 6,942 | 5,566 | 0 |
Operating Income | -8,300 | -6,942 | -5,566 | N/A |
Other Income | 90 | 87 | 352 | 0 |
Pre-tax Income | -8,210 | -6,855 | -5,214 | 0 |
Net Income Continuous | -8,210 | -6,855 | -5,214 | N/A |
Net Income | $-8,210 | $-6,855 | $-5,214 | $N/A |
EPS Basic Total Ops | -7.50 | -7.64 | -6.13 | N/A |
EPS Basic Continuous Ops | -7.50 | -7.64 | -6.13 | N/A |
EPS Diluted Total Ops | -7.50 | -7.64 | -6.13 | N/A |
EPS Diluted Continuous Ops | -7.50 | -7.64 | -6.13 | N/A |
EBITDA(a) | $-8,131 | $-6,738 | $-5,566 | $N/A |